INOVIO Pharmaceuticals, Inc.
INOVIO Pharmaceuticals, Inc. (Nasdaq: INO) is a clinical-stage biotechnology company developing DNA medicines for HPV-associated diseases, cancer, and infectious diseases. Its platform combines engineered DNA plasmids, which direct cells to produce disease-targeting proteins, with proprietary CELLECTRA electroporation… From the company’s description.
Over the twelve months to Jun 30, 2026, INOVIO Pharmaceuticals, Inc. reported a net loss of $67.43M. Operations used $80.58M in cash. In fiscal 2025, it reported revenue of $0.07M, down 70.0% from fiscal 2024, and a net loss of $84.95M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What INOVIO Pharmaceuticals, Inc. does
In the company’s own words
INOVIO Pharmaceuticals, Inc. (Nasdaq: INO) is a clinical-stage biotechnology company developing DNA medicines for HPV-associated diseases, cancer, and infectious diseases. Its platform combines engineered DNA plasmids, which direct cells to produce disease-targeting proteins, with proprietary CELLECTRA electroporation devices designed to deliver the plasmids into cells. The lead candidate, INO-3107, is under FDA review as a potential treatment for adults with recurrent respiratory papillomatosis, a disease that often requires repeated surgery. Other programs address HPV-related cancers and precancers, glioblastoma and other cancers, Ebola, HIV, and COVID-19; earlier-stage platforms include DNA-encoded antibodies and proteins. INOVIO has no reportable business segments described in its operations and earns revenue from licensing, milestones, and collaborative research and development rather than product sales. All product candidates remain in research and development. For fiscal 2025, the company reports no product-sale revenue. Its CELLECTRA and SynCon technologies support its development programs, and partners include pharmaceutical companies, government agencies, and academic institutions. Its website is https://www.inovio.com/.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- PLYMOUTH MEETING, PA
- Fiscal year end
- December
- CIK
- 1055726
- SIC
- 2834
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns INOVIO Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · INOVIO Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do INOVIO Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of INOVIO Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in INOVIO Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”